Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01765543
Registration number
NCT01765543
Ethics application status
Date submitted
9/01/2013
Date registered
10/01/2013
Date last updated
15/12/2016
Titles & IDs
Public title
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
Query!
Scientific title
A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study to Investigate the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 960 mg of Vemurafenib
Query!
Secondary ID [1]
0
0
2012-003142-33
Query!
Secondary ID [2]
0
0
GO28052
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Malignant Melanoma, Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Rifampin
Treatment: Drugs - Vemurafenib
Experimental: Vemurafenib + Rifampin - There will be 3 intervention periods in the study: Period A (Days 1 to 7), Period B (Days 8 to 16), and Period C (Days 17 to 24). Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 milligrams (mg) as film-coated tablets orally alone on Day 1 (Period A); with rifampin (at a dose of 600 mg as capsules orally) on Day 17 (Period C); and rifampin alone at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 16 (Period B) and from Days 18 through 23 (Period C).
Treatment: Drugs: Rifampin
Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
Treatment: Drugs: Vemurafenib
Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Area Under the Plasma Concentration Time-curve From Zero to the Last Measurable Concentration Time Point (AUClast) of Vemurafenib
Query!
Assessment method [1]
0
0
AUClast is the area under the vemurafenib plasma concentration versus time curve from time zero to the time of last measured concentration of vemurafenib (Tlast). Area under the curve (AUC) is a measure of the plasma concentration of a drug over time. AUClast is presented in micrograms times (*) hour per milliliter (mcg*h/mL).
Query!
Timepoint [1]
0
0
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Query!
Primary outcome [2]
0
0
Area Under the Plasma Concentration Time-curve From Zero to Extrapolated Infinite Time (AUC[0-inf]) of Vemurafenib
Query!
Assessment method [2]
0
0
AUC(0-inf) is the AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). AUC is a measure of the plasma concentration of a drug over time. AUC(0-inf) is presented in mcg*h/mL.
Query!
Timepoint [2]
0
0
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Query!
Primary outcome [3]
0
0
Maximum Observed Plasma Concentration (Cmax) of Vemurafenib
Query!
Assessment method [3]
0
0
Cmax is the maximum observed plasma vemurafenib concentration, presented in microgram per milliliter (mcg/mL).
Query!
Timepoint [3]
0
0
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Query!
Eligibility
Key inclusion criteria
- Participants with either unresectable Stage IIIc or Stage IV metastatic melanoma
positive for the BRAF V600 mutation or other malignant tumor type that harbors a
V600-activating mutation of BRAF, as determined by results of cobas® 4800 BRAF V600
mutation test or a Deoxyribonucleic acid (DNA) sequencing method, and who have no
acceptable standard treatment options
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- Life expectancy of greater than or equal to (>/=) 12 weeks
- Full recovery from the effects of any major surgery or significant traumatic injury
within 14 days prior to the first dose of study treatment
- Adequate hematologic and end organ function
- Female participants of childbearing potential and male participants with partners of
childbearing potential must agree to always use 2 effective methods of contraception
- Negative serum pregnancy test within 7 days prior to commencement of dosing in women
of childbearing potential
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of first dose
of study drug
- Requirement for immediate or urgent treatment with daily vemurafenib and for whom the
intermittent schedule of vemurafenib employed during the 24-day period for this trial
is not clinically acceptable
- Allergy or hypersensitivity to components of the vemurafenib formulation
- Experimental therapy within 4 weeks prior to first dose of study drug
- Major surgical procedure or significant traumatic injury within 14 days prior to first
dose of study drug, or anticipation of the need for major surgery during study
treatment
- Prior anti-cancer therapy within 28 days before the first dose of study drug
- History of clinically significant cardiac or pulmonary dysfunction
- History of symptomatic congestive heart failure of any New York Heart Association
class or serious cardiac arrhythmia requiring treatment
- History of myocardial infarction within 6 months prior to first dose of study drug
- Current dyspnea at rest, owing to complications of advanced malignancy or any
requirement for supplemental oxygen to perform activities of daily living
- History of congenital long QT syndrome or corrected QT interval (QTc) greater than (>)
450 milliseconds
- Active central nervous system lesions
- Uncontrolled or poorly controlled diabetes
- Current severe, uncontrolled systemic disease
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
27
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Ohio
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Texas
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
RS
Query!
Country [6]
0
0
Croatia
Query!
State/province [6]
0
0
Varazdin
Query!
Country [7]
0
0
Croatia
Query!
State/province [7]
0
0
Zagreb
Query!
Country [8]
0
0
Egypt
Query!
State/province [8]
0
0
Alexandria
Query!
Country [9]
0
0
Egypt
Query!
State/province [9]
0
0
Cairo
Query!
Country [10]
0
0
Egypt
Query!
State/province [10]
0
0
Dakahlia
Query!
Country [11]
0
0
Egypt
Query!
State/province [11]
0
0
Tanta
Query!
Country [12]
0
0
South Africa
Query!
State/province [12]
0
0
Cape Town
Query!
Country [13]
0
0
South Africa
Query!
State/province [13]
0
0
Port Elizabeth
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This open-label, multi-center, three-period, one-sequence study will investigate the effect
of rifampin on the PK of vemurafenib in participants with unresectable BRAFV600-mutation
positive metastatic melanoma or other malignant tumor type that harbors a V600-activating
mutation of BRAF without acceptable standard treatment options. Eligible participants will
have the option to continue treatment with vemurafenib as part of an extension study GO28399
(NCT01739764).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01765543
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01765543
Download to PDF